Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aspirin + atorvastatin is a fixed-dose combination of two small molecule drugs used primarily for the prevention of cardiovascular events such as heart attack and stroke. Aspirin acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase-1 (COX-1), thereby reducing thromboxane A2 production and preventing platelet aggregation. Atorvastatin is a statin that inhibits HMG-CoA reductase to lower cholesterol synthesis in the liver; it reduces low-density lipoprotein (LDL) cholesterol and triglycerides while increasing high-density lipoprotein (HDL) cholesterol. The combination provides additive benefits in reducing vascular inflammation and improving endothelial function beyond monotherapy with either agent alone. It is indicated for patients at high risk of cardiovascular disease or those who have undergone procedures such as coronary artery bypass grafting[4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + atorvastatin.